Search

Your search keyword '"Cassetti, I"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Cassetti, I" Remove constraint Author: "Cassetti, I"
88 results on '"Cassetti, I"'

Search Results

1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

2. Successful implementation of telemedicine and pharmacy enhanced HIV services as response to COVID-19 quarantine among health insured patients in Argentina

7. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study

8. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

9. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

10. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

11. The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)‐containing once‐daily highly active antiretroviral therapy (HAART)

12. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study

13. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

14. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection

16. Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up

22. A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

23. Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy

25. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

26. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

27. Unity is strength: creation and future actions for a consortium for HIV cure research in Latin America and the Caribbean 'Lac-Cura'.

28. Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort.

29. Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV.

30. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.

31. A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care.

32. [Impact of COVID-19 related lockdown on the metabolic profile of people with HIV infection in Argentina].

33. Mental Health, Coping, and Social Support Among People Living with HIV in the Americas: A Comparative Study Between Argentina and the USA During the SARS-CoV-2 Pandemic.

34. Cumulative Burden of Mental Health Factors and Engagement in HIV Care in Argentina.

36. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.

37. Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.

38. Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection.

39. Impact of COVID-19-Related Stress and Lockdown on Mental Health Among People Living With HIV in Argentina.

40. Mental health, coping, and social support among people living with HIV in the Americas: A comparative study between Argentina and the USA during the SARS-CoV-2 pandemic.

41. Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina.

42. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.

43. Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care.

44. Suicidality among nonadherent patients living with HIV in Buenos Aires, Argentina: prevalence and correlates.

45. Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial.

46. Implementation and uptake of the Conexiones y Opciones en la Argentina intervention: feasibility and acceptability.

47. Improving Adherence to Care Among "Hard to Reach" HIV-Infected Patients in Argentina.

48. [COGNITIVE SCREENING IN HIV-1 INFECTED YOUNG ADULTS AT BUENOS AIRES. PRELIMINARY DATA].

49. [Primary HIV resistance in Buenos Aires metropolitan area].

50. Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study.

Catalog

Books, media, physical & digital resources